A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Phase 3
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: SHR-A1912 Injection
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT06929624
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-3792 Injection
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06907628
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong, China
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Phase 2
Not yet recruiting
- Conditions
- Muscular Invasive Bladder Cancer (MIBC)
- Interventions
- Drug: SHR-A2102；Adebrelimab
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 840
- Registration Number
- NCT06879145
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
Phase 3
Recruiting
- Conditions
- Active Non-radiographic Axial Spondyloarthritis
- Interventions
- Drug: SHR-1314 InjectionDrug: SHR-1314 Placebo Injection
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT06860750
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1
Not yet recruiting
- Conditions
- Recurrent or Metastatic Cervical Cancer
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06859775
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
Phase 2
Recruiting
- Conditions
- NSCLC
- Interventions
- Drug: SHR-1826；Adebrelimab；SHR-8068；Bevacizumab
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06844474
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06840002
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
- Interventions
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06833307
- Locations
- 🇨🇳
Capital Medical University Affiliated Children's Hospital, Beijing, Beijing, China
🇨🇳Shanghai Huashan Hospital, Shanghai, Shanghai, China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06778031
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Phase 4
Not yet recruiting
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: Vunakizumab (IL-17A inhibitor)
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 1564
- Registration Number
- NCT06779097
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath